Structure and mechanism of arylamine N-Acetyltransferases

Current Topics in Medicinal Chemistry

Volumn 6, Issue 15, 2006, Pages 1641-1654

  Westwood, I M ^a   Kawamura, A ^a   Fullam, E ^a   Russell, A J ^a   Davies, S G ^a   Sim, Edith ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Arylamine N acetyltransferase; Catalytic mechanism; Crystal structure; Inhibitor studies; NAT; Phase II drug metabolism; SAR

Indexed keywords

2,4 THIAZOLIDINEDIONE; AMINOBENZOIC ACID DERIVATIVE; AROMATIC AMINE; ARYLAMINE ACETYLTRANSFERASE; ASPARTIC ACID; CYSTEINE; DRUG METABOLIZING ENZYME; ENZYME INHIBITOR; HETEROCYCLIC AMINE; HISTIDINE; HYDRAZIDE DERIVATIVE; HYDRAZINE DERIVATIVE; HYDROXYLAMINE; ISOENZYME; LIGAND;

BIOTRANSFORMATION; CATALYSIS; COMPUTER MODEL; CRYSTAL STRUCTURE; CRYSTALLIZATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME STRUCTURE; ENZYME SUBSTRATE; EUKARYOTE; HUMAN; MOLECULAR MODEL; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PHARMACOGENETICS; PREDICTION; PROKARYOTE; PROTEIN FAMILY; PROTEIN INTERACTION; RESIDUE ANALYSIS; REVIEW; SALMONELLA TYPHIMURIUM; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; COMPUTER SIMULATION; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 33748094672     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606778108979     Document Type: Review

References (87)

1. Hanna, P. E. N-acetyltransferases, O-acetyltransferases, and N,O-acetyltransferases: enzymology and bioactivation. Adv. Pharmacol. 1994, 27, 401-430.
2. Guengerich, F. P. Metabolic activation of carcinogens. Pharmacol. Ther. 1992, 54(1), 17-61.
3. Bleland, F. A.; Kadlubar, F. F. Metabolic activation and DNA adducts of aromatic amines and nitroaromatic hydrocarbons. In Handbook of Experimental Pharmacology; Cooper, C. S.; Grover, P. L.; Eds.; Springer-Verlag: New York, 1990; pp 267-325.
4. Grant, D. M. Molecular genetics of the N-acetyltransferases. Pharmacogenetics 1993, 3(1), 45-50.
5. Hein, D. W. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat. Res. 2002, 506-507, 65-77.
6. Dupret, J. M. Rodrigues-Lima, F.; Structure and regulation of the drug-metabolizing enzymes arylamine N-acetyltransferases. Curr. Med. Chem. 2005, 12(3), 311-318.
7. Blum, M.; Grant D. M.; McBride, W.; Heim, M.; Meyer, U. A. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression DNA and Cell Biology 1990, 9(3), 193-203.
8. Ohsako, S.; Deguchi, T. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J. Biol. Chem. 1990, 265(8), 4630-4634.
9. Grant, D. M.; Blum, M.; Beer, M.; Meyer, U. A. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol. Pharmacol. 1991, 39(2), 184-191.
10. Minchin, R. F.; Reeves, P. T.; Teitel, C. H.; McManus, M. E.; Mojarrabi, B.; Ilett, K. F.; Kadlubar, F. F. N-and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in COS-1 cells. Biochem. Biophys. Res. Commun. 1992, 185(3), 839-844.
11. Vatsis, K. P.; Weber, W. W.; Bell, D. A.; Dupret, J. M.; Evans, D. A.; Grant, D. M.; Hein, D. W.; Lin, H. J.; Meyer, U. A.; Relling, M. V.; Sim, E.; Suzuki, T.; Yamazoe, Y. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995, 5(1), 1-17.
12. Pompeo, F.; Brooke, E.; Kawamura, A.; Mushtaq, A.; Sim, E. The pharmacogenetics of NAT: structural aspects. Pharmacogenomics 2002, 3(1), 19-30.
13. Upton, A.; Johnson, N.; Sandy, J.; Sim, E. Arylamine N-acetyltransferases - of mice, men and microorganisms. Trends Pharmacol. Sci. 2001, 22(3), 140-146.
14. Jenne, J. W. Partial purification and properties of the isoniazid transacetylase in human liver: its relationship to the acetylation of p-aminosalicylic acid. J. Clin. Invest. 1965, 44, 1992-2002.
15. Hickman, D.; Pope, J.; Patil, S. D.; Fakis, G.; Smelt, V.; Stanley, L. A.; Payton, M.; Unadkat, J. D.; Sim, E. Expression of arylamine N-acetyltransferase in human intestine. Gut 1998, 42(3), 402-409.
16. Sasaki, Y.; Ohsako, S.; Deguchi, T. Molecular and genetic analyses of arylamine N-acetyltransferase polymorphism of rabbit liver. J. Biol. Chem. 1991, 266(20), 13243-13250.
17. Andres, H. H.; Vogel, R. S.; Tarr, G. E.; Johnson, L.; Weber, W. W. Purification, physicochemical, and kinetic properties of liver acetyl-CoA:arylamine N-acetyltransferase from rapid acetylator rabbits. Mol. Pharmacol. 1987, 31(4), 446-456.
18. Kelly, S. L.; Sim, E. Arylamine N-acetyltransferase in Balb/c mice: identification of a novel mouse isoenzyme by cloning and expression in vitro. Biochem. J. 1994, 302(2), 347-353.
19. Martell, K.; Vatsis, K.; Weber, W. Molecular genetic basis of rapid and slow acetylation in mice. Mol. Pharmacol. 1991, 40, 218-227.
20. Doll, M. A.; Hein, D. W. Cloning, sequencing and expression of NAT1 and NAT2 encoding genes from rapid and slow acetylator inbred rats. Pharmacogenetics 1995, 5(4), 247-251.
21. Ferguson, R. J.; Doll, M. A.; Rustan, T. D.; Baumstark, B. R.; Hein, D. W. Syrian hamster monomorphic N-acetyltransferase (NAT1) alleles: amplification, cloning, sequencing, and expression in E. coli. Pharmacogenetics 1994, 4(2), 82-90.
22. Ferguson, R. J.; Doll, M. A.; Baumstark, B. R.; Hein, D. W. Polymorphic arylamine N-acetyltransferase encoding gene (NAT2) from homozygous rapid and slow acetylator congenic Syrian hamsters. Gene 1994, 140(2), 247-249.
23. Trepanier, L. A.; Cribb, A. E.; Spielberg, S. P.; Ray, K. Deficiency of cytosolic arylamine N-acetylation in the domestic cat and wild felids caused by the presence of a single NAT1-like gene. Pharmacogenetics 1998, 8(2), 169-179.
24. Muenzen, J.; Cerecedo, L.; Sherwin, C. Comparative metabolism of certain aromatic acids. J. Biol. Chem. 1926, 67, 469-476.
25. Trepanier, L. A.; Ray, K.; Winand, N. J.; Spielberg, S. P.; Cribb, A. E. Cytosolic arylamine N-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes. Biochem. Pharmacol. 1997, 54(1), 73-80.
26. Marshall, E. K., Jr.; Cutting, W. C.; Emerson, K. Acetylation of para-aminobenzene sulfonamide in the animal organism. Science 1936, 85, 202-203.
27. Marshall, E. K., Jr. Acetylation of sulfonamides in the dog. J. Biol. Chem. 1954, 211(1), 499-503.
28. Riddle, B.; Jencks, W. P. Acetyl-coenzyme A: arylamine N-acetyltransferase. Role of the acetyl-enzyme intermediate and the effects of substituents on the rate. J. Biol. Chem. 1971, 246(10), 3250-3258.
29. Lipmann, F. Acetylation of sulfanilamide by liver homogenates and extracts. J. Biol. Chem. 1945, 160, 173-190.
30. Deguchi, T.; Sakamoto, Y.; Sasaki, Y.; Uyemura, K. Arylamine N-acetyltransferase from chicken liver. I. Monoclonal antibodies, immunoaffinity purification, and amino acid sequences. J. Biol. Chem. 1988, 263(16), 7528-7533.
31. Ohsako, S.; Ohtomi, M.; Sakamoto, Y.; Uyemura, K.; Deguchi, T. Arylamine N-acetyltransferase from chicken liver II. Cloning of cDNA and expression in Chinese hamster ovary cells. Journal of Biological Chemistry 1988, 263(16), 7534-7538.
32. Watanabe, M.; Sofuni, T.; Nohmi, T. Involvement of Cys69 residue in the catalytic mechanism of N-hydroxyarylamine O-acetyltransferase of Salmonella typhimurium. Sequence similarity at the amino acid level suggests a common catalytic mechanism of acetyltransferase for S. typhimurium and higher organisms. J. Biol. Chem. 1992, 267, 8429-8436.
33. Sandy, J.; Mushtaq, A.; Holton, S. J.; Schartau, P.; Noble, M. E.; Sim, E. Investigation of the catalytic triad of arylamine N-acetyltransferases: essential residues required for acetyl transfer to arylamines. Biochem. J. 2005, 390(1), 115-123.
34. Payton, M.; Mushtaq, A.; Yu, T. W.; Wu, L. J.; Sinclair, J.; Sim, E. Eubacterial arylamine N-acetyltransferases - identification and comparison of 18 members of the protein family with conserved active site cysteine, histidine and aspartate residues. Microbiology 2001, 147(5), 1137-1147.
35. Delomenie, C.; Fouix, S.; Longuemaux, S.; Brahimi, N.; Bizet, C.; Picard, B.; Denamur, E.; Dupret, J.-M. Identification and Functional Characterization of Arylamine N-Acetyltransferases in Eubacteria: Evidence for Highly Selective Acetylation of 5-Aminosalicylic Acid. J. Bacteriol. 2001, 183(11), 3417-3427.
36. Sandy, J.; Mushtaq, A.; Kawamura, A.; Sinclair, J.; Sim, E.; Noble, M. The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis - an enzyme which inactivates the anti-tubercular drug, isoniazid. J. Mol. Biol. 2002, 318(4), 1071-1083.
37. Westwood, I. M.; Holton, S. J.; Rodrigues-Lima, F.; Dupret, J. M.; Bhakta, S.; Noble, M. E.; Sim, E. Expression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase. Biochem. J. 2005, 385(2), 605-612.
38. Holton, S. J.; Dairou, J.; Sandy, J.; Rodrigues-Lima, F.; Dupret, J. M.; Noble, M.; Sim, E. Structure of Mesorhizobium loti arylamine N-acetyltransferase 1. Acta Crystallogr. F 2005, 61, 14-16.
39. Sinclair, J. C.; Sandy, J.; Delgoda, R.; Sim, E.; Noble, M. E. Structure of arylamine N-acetyltransferase reveals a catalytic triad. Nat. Struct. Biol. 2000, 7(7), 560-564.
40. Sandy, J.; Holton, S.; Fullam, E.; Sim, E.; Noble, M. Binding of the anti-tubercular drug isoniazid to the arylamine N-acetyltransferase protein from Mycobacterium smegmatis. Protein Sci. 2005, 14(3), 775-782.
41. Kawamura, A.; Sandy, J.; Upton, A.; Noble, M.; Sim, E. Structural investigation of mutant Mycobacterium smegmatis arylamine N-acetyltransferase: a model for a naturally occurring functional polymorphism in Mycobacterium tuberculosis arylamine N-acetyltransferase. Protein Expr. Purif. 2003, 27(1), 75-84.
42. Jones, T.; Zou, J. Improved method for building models in electron density maps and the location of errors in these models. Acta Crystallogr. A 1991, 47, 110-119.
43. Kawamura, A.; Graham, J.; Mushtaq, A.; Tsiftsoglou, S. A.; Vath, G. M.; Hanna, P. E.; Wagner, C. R.; Sim, E. Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by high-throughput screening. Biochem. Pharmacol. 2005, 69(2), 347-359.
44. Delgoda, R.; Lian, L. Y.; Sandy, J.; Sim, E. NMR investigation of the catalytic mechanism of arylamine N-acetyltransferase from Salmonella typhimurium. Biochim. Biophys. Acta 2003, 1620(1-3), 8-14.
45. Mushtaq, A.; Payton, M.; Sim, E. The COOH terminus of arylamine N-acetyltransferase from Salmonella typhimurium controls enzymic activity. J. Biol. Chem. 2002, 277(14), 12175-12181.
46. Hein, D. W.; Doll, M. A.; Fretland, A. J.; Leff, M. A.; Webb, S. J.; Xiao, G. H.; Devanaboyina, U. S.; Nangju, N. A.; Feng, Y. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomarkers Prev. 2000, 9(1), 29-42.
47. Dupret, J. M.; Grant, D. M. Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase expressed in Escherichia coli. Evidence for direct involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2. J. Biol. Chem. 1992, 267(11), 7381-7385.
48. Wang, H.; Vath, G. M.; Gleason, K. J.; Hanna, P. E.; Wagner, C. R. Probing the mechanism of hamster arylamine N-acetyltransferase 2 acetylation by active site modification, site-directed mutagenesis, and pre-steady state and steady state kinetic studies. Biochemistry 2004, 43(25), 8234-8246.
49. Dupret, J.-M.; Goodfellow, G.; Janezic, S.; Grant, D. Structure-function studies of human arylamine N-acetyltransferases NAT1 and NAT2. J. Biol. Chem. 1994, 269, 26830-26835.
50. Goodfellow, G. H.; Dupret, J. M.; Grant, D. M. Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. Biochem. J. 2000, 348(1), 159-166.
51. Summerscales, J. E.; Josephy, P. D. Human acetyl CoA:arylamine N-acetyltransferase variants generated by random mutagenesis. Mol. Pharmacol. 2004, 65(1), 220-226.
52. Cheon, H. G.; Hanna, P. E. Effect of group-selective modification reagents on arylamine N-acetyltransferase activities Biochem. Pharmacol. 1992, 43(10), 2255-2268.
53. Delomenie, C.; Goodfellow, G. H.; Krishnamoorthy, R.; Grant, D. M.; Dupret, J. M. Study of the role of the highly conserved residues Arg9 and Arg64 in the catalytic function of human N-acetyltransferases NAT1 and NAT2 by site-directed mutagenesis. Biochem. J. 1997, 323(1), 207-215.
54. Rodrigues-Lima, F.; Dupret, J. M. 3D model of human arylamine N-acetyltransferase 2: structural basis of the slow acetylator phenotype of the R64Q variant and analysis of the active-site loop. Biochem. Biophys. Res. Commun. 2002, 291(1), 116-123.
55. Sinclair, J.; Sim, E. A fragment consisting of the first 204 amino-terminal amino acids of human arylamine N-acetyltransferase one (NAT1) and the first transacetylation step of catalysis, Biochem. Pharmacol. 1997, 53(1), 11-16.
56. Hubbard, A. L.; Moyes, C.; Wyllie, A. H.; Smith, C. A.; Harrison, D. J. N-acetyl transferase 1: two polymorphisms in coding sequence identified in colorectal cancer patients. Br. J. Cancer 1998, 77(6), 913-916.
57. Hughes, N. C.; Janezic, S. A.; McQueen, K. L.; Jewett M. A.; Castranio, T.; Bell, D. A.; Grant, D. M. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. Pharmacogenetics 1998, 8(1), 55-66.
58. Rodrigues-Lima, F.; Delomenie, C.; Goodfellow, G. H.; Grant D. M.; Dupret, J. M. Homology modelling and structural analysis of human arylamine N-acetyltransferase NAT1: evidence for the conservation of a cysteine protease catalytic domain and an activesite loop. Biochem. J. 2001, 356(2), 327-334.
59. Marti-Renom, M. A.; Stuart, A. C.; Fiser, A.; Sanchez, R.; Melo, F.; Sali, A. Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol Struct. 2000, 29, 291-325.
60. Sali, A.; Potterton, L.; Yuan, F.; van Vlijmen, H.; Karplus, M. Evaluation of comparative protein modeling by MODELLER. Proteins 1995, 23(3), 318-326.
61. Cleland, W. W. The kinetics of enzyme-catalyzed reactions with two or more substrates or products. I. Nomenclature and rate equations. Biochim. Biophys. Acta 1963, 67, 104-137.
62. Bessman, S. P.; Lipmann, F. The enzymatic transacetylation between aromatic amines. Arch. Biochem. Biophys. 1953, 46(1), 252-254.
63. Jenne, J. W.; Boyer, P. D. Kinetic characteristics of the acetylation of isoniazid and p-aminosalicylic acid by a liver-enzyme preparation Biochim. Biophys. Acta 1962, 65, 121-127.
64. Weber, W. W.; Cohen, S. N. N-acetylation of drugs: isolation and properties of an N-acetyltransferase from rabbit liver. Mol. Pharmacol. 1967, 3(3), 266-273.
65. Andres, H. H.; Kolb, H. J.; Schreiber, R. J.; Weiss, L. Characterization of the active site, substrate specificity and kinetic properties of acetyl-CoA:arylamine N-acetyltransferase from pigeon liver. Biochim. Biophys. Acta 1983, 746(3), 193-201.
66. Andres, H. H.; Klem, A. J.; Schopfer, L. M.; Harrison, J. K.; Weber, W. W. On the active site of liver acetyl-CoA. Arylamine N-acetyltransferase from rapid acetylator rabbits (III/J). J. Biol. Chem. 1988, 263(16), 7521-7527.
67. Wang, H.; Liu, L.; Hanna, P. E.; Wagner, C. R. Catalytic mechanism of hamster arylamine N-acetyltransferase 2. Biochemistry 2005, 44(48), 15960.
68. Jencks, W. P.; Gresser, M.; Valenzuela, M. S.; Huneeus, F. C. Acetyl Coenzyme A: Arylamine Acetyltransferase (Measurement of the steady state concentration of the acetyl-enzyme intermediate). J. Biol. Chem. 1972, 247(12), 3756-3760.
69. Andres, H. H.; Klem, A. J.; Szabo, S. M.; Weber, W. W. New spectrophotometric and radiochemical assays for acetyl-CoA: arylamine N-acetyltransferase applicable to a variety of arylamines. Anal. Biochem. 1985, 145(2), 367-375.
70. Hickman, D.; Palamanda, J. R.; Unadkat, J. D.; Sim, E. Enzyme kinetic properties of human recombinant arylamine N-acetyltransferase 2 allotypic variants expressed in Escherichia coli. Biochem. Pharmacol. 1995, 50(5), 697-703.
71. de León, J. H.; Vatsis, K. P.; Weber, W. W. Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1. Mol. Pharmacol. 2000, 58(2), 288-299.
72. Cornish-Bowden, A. In Fundamentals of Enzyme Kinetics; Portland Press: Cambridge, 1995; pp 147-150.
73. Wang, H.; Vath, G. M.; Kawamura, A.; Bates, C. A.; Sim, E.; Hanna, P. E.; Wagner, C. R. Over-expression, purification, and characterization of recombinant human arylamine N-acetyltransferase 1. Protein J. 2005, 24(2), 65-77.
74. Brooke, E. W.; Davies, S. G.; Mulvaney, A. W.; Pompeo, F.; Sim, E.; Vickers, R. J. An approach to identifying novel substrates of bacterial arylamine N-acetyltransferases, Bioorg. Med. Chem. 2003, 11(7), 1227-1234.
75. Minchin, R. F. Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells. Biochem. J. 1995, 307(1), 1-3.
76. Ward, A.; Summers, M. J.; Sim, E. Purification of recombinant human N-acetyltransterase type 1 (NAT1) expressed in E. coli and characterization of its potential role in folate metabolism. Biochem. Pharmacol. 1995, 49(12), 1759-1767.
77. Cheon, H. G.; Boteju, L. W.; Hanna, P. E. Affinity alkylation of hamster hepatic arylamine N-acetyltransferases: isolation of a modified cysteine residue. Mol. Pharmacol. 1992, 42(1), 82-93.
78. Guo, Z.; Wagner, C. R.; Hanna P. E. Mass spectrometric investigation of the mechanism of inactivation of hamster arylamine N-acetyltransferase 1 by N-hydroxy-2-acetylaminofluorene. Chem. Res. Toxicol. 2004, 17(3), 275-286.
79. Sticha, K. R.; Bergstrom, C. P.; Wagner, C. R.; Hanna, P. E. Characterization of hamster recombinant monomorphic and polymorphic arylamine N-acetyltransferases: bioactivation and mechanism-based inactivation studies with N-hydroxy-2-acetylaminofluorene. Biochem. Pharmacol. 1998, 56(1), 47-59.
80. Wang, H.; Wagner, C. R.; Hanna, P. E. Irreversible inactivation of arylamine N-acetyltransferases in the presence of N-hydroxy-4-acetylaminobiphenyl: a comparison of human and hamster enzymes. Chem. Res, Toxicol. 2005, 18(2), 183-197.
81. Wang, H.; Guo, Z.; Vath, G. M.; Wagner, C. R.; Hanna, P. E. Chemical modification of hamster arylamine N-acetyltransferase 2 with isozyme-selective and nonselective N-arylbromoacetamido reagents. Protein J. 2004, 23(2), 153-166.
82. Dairou, J.; Atmane, N.; Dupret, J. M.; Rodrigues-Lima, F. Reversible inhibition of the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 by S-nitrosothiols. Biochem. Biophys. Res. Commun. 2003, 307(4), 1059-1065.
83. Dairou, J.; Atmane, N.; Rodrigues-Lima, F.; Dupret, J. M. Peroxynitrite irreversibly inactivates the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) in human breast cancer cells: a cellular and mechanistic study. J. Biol. Chem. 2004, 279(9), 7708-7714.
84. Brooke, E. W.; Davies, S. G.; Mulvaney, A. W.; Okada, M.; Pompeo, F.; Sim, E.; Vickers, R. J.; Westwood, I. M. Synthesis and in vitro evaluation of novel small molecule inhibitors of bacterial arylamine N-acetyltransferases (NATs). Bioorg. Med. Chem. Lett. 2003, 13(15), 2527-2530.
85. Morris, G.; Goodsell, D.; Halliday, R.; Huey, R.; Hart, W.; Belew, R.; Olson, A. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19(14), 1639-1662.
86. Miners, J. O.; Smith, P. A.; Sorich, M. J.; McKinnon, R. A.; Mackenzie, P. I. Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu. Rev. Pharmacol. Toxicol. 2004, 44, 1-25.
87. Polanski, J. Self-organizing neural networks for pharmacophore mapping. Adv. Drug Deliv. Rev. 2003, 55(9), 1149-1162.